This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or registerLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up
PortfolioSupport & ResourcesMaterialsVideosPodcasts
Rheumatology1

Inflammation is a critical response to potential danger signals and damage to organs in our body, which is orchestrated by our immune system. However, with autoimmune diseases such as rheumatoid arthritis, lupus, ulcerative colitis, Crohn’s disease, and many others, our immune system mistakenly turns against some of our own healthy cells, tissues and organs. These painful and debilitating conditions take an immense toll on people’s quality of life and many of these diseases are difficult to manage with existing treatments that may provide only symptomatic relief.

For decades, we have relied on steroids to suppress immune response. Though an important option, steroids come with many potentially harmful side effects.2 Fortunately, science has continued to advance, and today we have the opportunity to transform the management of immune-mediated inflammatory diseases with new classes of therapies that target specific key proteins and pathways in the body.

As science evolves beyond broad immunosuppression and into more selective agents, patients living with autoimmune and inflammatory disease have new treatment options.

Portfolio

Learn more about Pfizer's treatment options in Rheumatology

Explore Pfizer’s portfolio Loading
Support and resources

Access materials to support you and your patients

View available resources Loading
References:https://www.pfizer.com/science/focus-areas/immunology-inflammation/research (accessed 04 January 2023)Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023;82:3–18.
PP-UNP-IRL-0338. January 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.  Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0832. October 2024
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0832. October 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0832. October 2024

Yes No